Literature DB >> 34571188

Suppression of C-C chemokine receptor 1 is a key regulation for colon cancer chemoprevention in AOM/DSS mice by fucoxanthin.

Masaru Terasaki1, Shion Ono2, Saki Hashimoto2, Atsuhito Kubota2, Hiroyuki Kojima3, Tohru Ohta4, Takuji Tanaka5, Hayato Maeda6, Kazuo Miyashita7, Michihiro Mutoh8.   

Abstract

Fucoxanthin (Fx) has shown potential cancer chemopreventive functions in a carcinogenic murine azoxymethane/dextran sodium sulfate (AOM/DSS) model. However, the molecular mechanisms based on transcriptome profiles in vivo remain poorly understood. We investigated Fx-dependent alterations of the transcriptome with cancer-associated proteins in colorectal mucosal tissue obtained from AOM/DSS mice with or without Fx treatment. Fx administration (50 mg/kg body weight for 14 weeks) significantly prevented the onset of colorectal adenocarcinoma in AOM/DSS mice. A transcriptome analysis revealed that 11 signals, including adhesion, cell cycle, chemokine receptor, interleukin, MAPK, PI3K/AKT, p53, RAS, STAT, TGF-β, and Wnt were remarkably altered by Fx administration. In particular, chemokine (C-C motif) receptor 1 (Ccr1), which is contained in a gene set related to cytokine-cytokine receptor interactions, was the only significantly down-regulated gene after Fx administration for both 7 and 14 weeks. CCR1, AKT, Cyclin D1, and Smad2 were found to play central roles in the 11 signals shown above. Fx administration significantly down-regulated CCR1 (0.3- and 0.5-fold in mucosal crypts and lamina propria, respectively), pAKT(Ser473) (0.2-fold in mucosal crypts), Cyclin D1 (0.4-fold in mucosal crypts), and pSmad2(Ser465/467) (0.7-fold in mucosal crypts) compared with proteins in these tissues of control mice after Fx administration for 14 weeks. Our findings suggested that Fx exerts a chemopreventive effect in AOM/DSS mice through attenuation of CCR1 expression along with 11 cancer-associated signals.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  C-C chemokine receptor 1; Cancer prevention; Carotenoid; Colorectal cancer; Fucoxanthin

Mesh:

Substances:

Year:  2021        PMID: 34571188     DOI: 10.1016/j.jnutbio.2021.108871

Source DB:  PubMed          Journal:  J Nutr Biochem        ISSN: 0955-2863            Impact factor:   6.048


  5 in total

1.  Requirement of CLIC4 Expression in Human Colorectal Cancer Cells for Sensitivity to Growth Inhibition by Fucoxanthinol.

Authors:  Reo Yokoyama; Ayumi Kushibiki; Shiori Yamada; Atsuhito Kubota; Hiroyuki Kojima; Tohru Ohta; Junichi Hamada; Hayato Maeda; Michihiro Mutoh; Masaru Terasaki
Journal:  Cancer Genomics Proteomics       Date:  2022 Jul-Aug       Impact factor: 3.395

Review 2.  Natural Marine Products: Anti-Colorectal Cancer In Vitro and In Vivo.

Authors:  Ningning Han; Jianjiang Li; Xia Li
Journal:  Mar Drugs       Date:  2022-05-25       Impact factor: 6.085

Review 3.  A Systematic Review on Marine Algae-Derived Fucoxanthin: An Update of Pharmacological Insights.

Authors:  Md Mohibbullah; Md Nazmul Haque; Abdullah Al Mamun Sohag; Md Tahmeed Hossain; Md Sarwar Zahan; Md Jamal Uddin; Md Abdul Hannan; Il Soo Moon; Jae-Suk Choi
Journal:  Mar Drugs       Date:  2022-04-22       Impact factor: 6.085

Review 4.  Anti-colorectal cancer effects of seaweed-derived bioactive compounds.

Authors:  Yunhua Fu; Dong Xie; Yinghao Zhu; Xinyue Zhang; Hao Yue; Kai Zhu; Zifeng Pi; Yulin Dai
Journal:  Front Med (Lausanne)       Date:  2022-08-19

5.  Fucoxanthin Prevents Pancreatic Tumorigenesis in C57BL/6J Mice That Received Allogenic and Orthotopic Transplants of Cancer Cells.

Authors:  Wataru Murase; Yukino Kamakura; Serina Kawakami; Ayaka Yasuda; Momoka Wagatsuma; Atsuhito Kubota; Hiroyuki Kojima; Tohru Ohta; Mami Takahashi; Michihiro Mutoh; Takuji Tanaka; Hayato Maeda; Kazuo Miyashita; Masaru Terasaki
Journal:  Int J Mol Sci       Date:  2021-12-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.